{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:12:50Z","timestamp":1792977170121,"version":"4.5.0"},"reference-count":128,"publisher":"Baishideng Publishing Group Inc.","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2014]]},"DOI":"10.3748\/wjg.v20.i29.9675","type":"journal-article","created":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T00:33:34Z","timestamp":1407717214000},"page":"9675","source":"Crossref","is-referenced-by-count":86,"title":["Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease"],"prefix":"10.3748","volume":"20","author":[{"given":"Sara","family":"Renna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.12.002"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.07.010"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.09.002"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12290"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn&rsquo;s disease. Gut 1994;35:360-362.","DOI":"10.1136\/gut.35.3.360"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000545"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.64"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03925.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000067"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Nikfar S, Mirfazaelian H, Abdollahi M. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn&rsquo;s disease: a systematic review and meta-analysis of placebo-controlled trials. Curr Pharm Des 2010;16:3684-3698.","DOI":"10.2174\/138161210794079236"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1671-5"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"L&eacute;mann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y. A randomized, double-blind, controlled withdrawal trial in Crohn&rsquo;s disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-1818.","DOI":"10.1053\/j.gastro.2005.03.031"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61302-7"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-1125.","DOI":"10.1136\/gut.2004.049460"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.01.004"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Reijasse D, Le Pendeven C, Cosnes J, Dehee A, Gendre JP, Nicolas JC, Beaugerie L. Epstein-Barr virus viral load in Crohn&rsquo;s disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 2004;10:85-90.","DOI":"10.1097\/00054725-200403000-00004"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20823"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.11.024"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.050"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.07.039"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.12.003"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1500-1"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04756.x"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21662"},{"key":"ref25","unstructured":"Arora S, Katkov W, Cooley J, Kemp JA, Johnston DE, Schapiro RH, Podolsky D. Methotrexate in Crohn&rsquo;s disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724-1729."},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Mat&eacute;-Jim&eacute;nez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:1227-1233.","DOI":"10.1097\/00042737-200012110-00010"},{"key":"ref27","unstructured":"Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, Shirin C, Reisfeld I, Broide E, Lavy A. Methotrexate in chronic active Crohn&rsquo;s disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203-2209."},{"key":"ref28","unstructured":"Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M. Methotrexate for the treatment of Crohn&rsquo;s disease. The North American Crohn&rsquo;s Study Group Investigators. N Engl J Med 1995;332:292-297."},{"key":"ref29","unstructured":"Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M. A comparison of methotrexate with placebo for the maintenance of remission in Crohn&rsquo;s disease. North American Crohn&rsquo;s Study Group Investigators. N Engl J Med 2000;342:1627-1632."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04873.x"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J. Tacrolimus for the treatment of fistulas in patients with Crohn&rsquo;s disease: a randomized, placebo-controlled trial. Gastroenterology 2003;125:380-388.","DOI":"10.1016\/S0016-5085(03)00877-1"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Gonz&aacute;lez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, Dur&aacute;n JG, Escartin P. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn&rsquo;s disease: a pilot study. Inflamm Bowel Dis 2005;11:8-15.","DOI":"10.1097\/00054725-200501000-00002"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn&rsquo;s disease perianal fistulae. Inflamm Bowel Dis 1999;5:239-245.","DOI":"10.1097\/00054725-199911000-00001"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn&rsquo;s disease. Gut 2000;47:436-440.","DOI":"10.1136\/gut.47.3.436"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007;13:129-134.","DOI":"10.1002\/ibd.20052"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn&rsquo;s disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007;13:245-253.","DOI":"10.1002\/ibd.20073"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn&rsquo;s disease: a single-center experience. Inflamm Bowel Dis 2008;14:7-12.","DOI":"10.1002\/ibd.20263"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-008-2229-y"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn&rsquo;s disease. Aliment Pharmacol Ther 2007;26:421-430.","DOI":"10.1111\/j.1365-2036.2007.03385.x"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn&rsquo;s disease resistant to standard therapies. Aliment Pharmacol Ther 2007;25:557-567.","DOI":"10.1111\/j.1365-2036.2006.03239.x"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, Ventura A. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther 2007;25:419-427.","DOI":"10.1111\/j.1365-2036.2006.03211.x"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318228349e"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987;17:962-971.","DOI":"10.1016\/S0190-9622(87)70285-0"},{"key":"ref44","unstructured":"Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993;11 Suppl 8:S117-S119."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn&rsquo;s disease. Inflamm Bowel Dis 2000;6:16-20.","DOI":"10.1097\/00054725-200002000-00003"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Wenzl HH, Hinterleitner TA, Aichbichler BW, Fickert P, Petritsch W. Mycophenolate mofetil for Crohn&rsquo;s disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 2004;19:427-434.","DOI":"10.1111\/j.1365-2036.2004.01856.x"},{"key":"ref47","unstructured":"Hafraoui S, Dewit O, Marteau P, Cosnes J, Colombel JF, Modigliani R, Cortot A, L&eacute;mann M. [Mycophenolate mofetil in refractory Crohn&rsquo;s disease after failure of treatments by azathioprine or methotrexate]. Gastroenterol Clin Biol 2002;26:17-22."},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn&rsquo;s disease? Am J Gastroenterol 2001;96:782-787.","DOI":"10.1111\/j.1572-0241.2001.03622.x"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum B&uuml;schenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn&rsquo;s disease. Gut 1999;44:625-628.","DOI":"10.1136\/gut.44.5.625"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.03.014"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.73"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"L&eacute;mann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L. Infliximab plus azathioprine for steroid-dependent Crohn&rsquo;s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054-1061.","DOI":"10.1053\/j.gastro.2006.02.014"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD. Adalimumab for maintenance of clinical response and remission in patients with Crohn&rsquo;s disease: the CHARM trial. Gastroenterology 2007;132:52-65.","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12499"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21835"},{"key":"ref56","unstructured":"Orlando A, Renna S, Mocciaro F, Cappello M, Di Mitri R, Orlando R, Modesto I, Randazzo C, Marino A, Crax&igrave; A. Long Term Adalimumab Efficacy In Steroid-dependent Crohn&rsquo;s Disease Patients. Gatroenterol J 2013;1 Supp 1:P1434."},{"key":"ref57","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn&rsquo;s disease. Crohn&rsquo;s Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035."},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn&rsquo;s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-333; quiz 591.","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004;10:333-338.","DOI":"10.1097\/00054725-200407000-00002"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D&rsquo;Haens G, Li J, Rosenfeld MR, Kent JD. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-838.","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i37.5219"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Regueiro M, Siemanowski B, Kip KE, Plevy S. Infliximab dose intensification in Crohn&rsquo;s disease. Inflamm Bowel Dis 2007;13:1093-1099.","DOI":"10.1002\/ibd.20177"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.01.002"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60304-9"},{"key":"ref65","unstructured":"Schreiber S, Reinisch W, Colombel JF. Early Crohn&rsquo;s disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology 2007;132:A985."},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn&rsquo;s disease. Gastroenterology 2006;130:650-656.","DOI":"10.1053\/j.gastro.2005.12.019"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.163642"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20927"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.01.035"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn&rsquo;s disease. Clin Gastroenterol Hepatol 2006;4:1248-1254.","DOI":"10.1016\/j.cgh.2006.06.025"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"ref72","unstructured":"Fasanmade A, Olson A, Bao W, Pendley C, Davis H, Mayer L. Relationship between infliximab pharmacokinetics and improvement in Crohn&rsquo;s disease. Gastroenterology 2002;122:A617-618."},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.9"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Feagan BG, Singh S, Lockton S, Hauenstein S, Ohrmund L, Croner LJ, Greenberg GR, Sandborn WJ, Rutgeerts PJ, Vermeire S. 565 novel in\ufb02iximab (IFX) and antibody-to-in\ufb02iximab (ATI) assays are predictive of disease activity in patients with Crohn&rsquo;s disease (CD). Gastroenterology 2012;142:S114.","DOI":"10.1016\/S0016-5085(12)60430-2"},{"key":"ref75","unstructured":"Li J, Chiu Y, Robinson A. Evaluation of potential correlations between serum adalimumab concentration and remission in patients with Crohn&rsquo;s disease in CLASSIC I and II. J Crohn&rsquo;s Colitis 2010;4:73."},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.07.062"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn&rsquo;s disease: a randomized controlled trial. Gastroenterology 2003;124:917-924.","DOI":"10.1053\/gast.2003.50145"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn&rsquo;s disease. Am J Gastroenterol 2008;103:944-948.","DOI":"10.1111\/j.1572-0241.2007.01638.x"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2010.536254"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22910"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.10.020"},{"key":"ref82","unstructured":"Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000;19:14-16."},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002;37:270-274.","DOI":"10.1007\/s005350200034"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53.","DOI":"10.1136\/gut.2005.068809"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21083"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, Ron Y, Reisfeld I, Broide E, Lavy A. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-1421.","DOI":"10.1053\/gast.1996.v110.pm8613046"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-356.","DOI":"10.7326\/0003-4819-110-5-353"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04073.x"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-1262.","DOI":"10.1136\/gut.2005.081794"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21853"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12118"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03764.x"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03841.x"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0b013e31829ebd83"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"D&rsquo;Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-1329.","DOI":"10.1053\/gast.2001.23983"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.","DOI":"10.1056\/NEJM199406303302601"},{"key":"ref97","unstructured":"Van Assche G, D&rsquo;Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D&rsquo;Hoore A, Penninckx F, Rutgeerts P. Randomized, double-blind comparison of 4 mg\/kg versus 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-1031."},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181e883dd"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Ford AC, Towler RJ, Moayyedi P, Chalmers DM, Axon AT. Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003;17:1365-1369.","DOI":"10.1046\/j.1365-2036.2003.01581.x"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Fellermann K, Steffen M, Stein J, Raedler A, H&auml;mling J, Ludwig D, Loeschke K, Stange EF. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:171-176.","DOI":"10.1046\/j.1365-2036.2000.00695.x"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Palaniappan S, Ford AC, Greer D, Everett SM, Chalmers DM, Axon AT, Hamlin PJ. Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1488-1492.","DOI":"10.1002\/ibd.20258"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Tan T, Lawrance IC. Use of mycophenolate mofetil in inflammatory bowel disease. World J Gastroenterol 2009;15:1594-1599.","DOI":"10.3748\/wjg.15.1594"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.","DOI":"10.1056\/NEJMoa050516"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.221127"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;CD005112.","DOI":"10.1002\/14651858.CD005112.pub2"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007;13:2328-2332.","DOI":"10.3748\/wjg.v13.i16.2328"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03811.x"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04531.x"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.03.018"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.048"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.06.010"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"J&auml;rnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karl&eacute;n P, Gr&auml;nn&ouml; C, Vilien M, Str&ouml;m M, Danielsson A, Verbaan H. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-1811.","DOI":"10.1053\/j.gastro.2005.03.003"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, Viscido A, Annese V, Riegler G, Meucci G. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007;26:747-756.","DOI":"10.1111\/j.1365-2036.2007.03415.x"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-88.","DOI":"10.1097\/00054725-200105000-00001"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, Boulton-Jones R, Williams A, Church N, Satsangi J. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26:411-419.","DOI":"10.1111\/j.1365-2036.2007.03383.x"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04435.x"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2011.26612"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21680"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.11.021"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61084-8"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010;48:297-308.","DOI":"10.5414\/CPP48297"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.183095"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(12)60431-4"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Panaccione R, Ghosh S, Middleton S, M&aacute;rquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3.","DOI":"10.1053\/j.gastro.2013.10.052"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.163279"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.021"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1159\/000338144"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v20\/i29\/9675.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:11:57Z","timestamp":1565723517000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v20\/i29\/9675.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":128,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v20.i29.9675","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}